Kiniksa Pharmaceuticals Stock Analysis

Kiniksa Stock Analysis Notes

About 89.0% of the company shares are owned by institutional investors. The book value of Kiniksa Pharmaceuticals was now reported as 6.05. The company has Price/Earnings To Growth (PEG) ratio of 0.25. Kiniksa Pharmaceuticals recorded a loss per share of 0.6. The entity had not issued any dividends in recent years. The firm had 1:1 split on the 28th of June 2024. Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda. Kiniksa Pharmaceuticals is traded on NASDAQ Exchange in the United States. To find out more about Kiniksa Pharmaceuticals contact Sanj Patel at 781 431 9100 or learn more at https://www.kiniksa.com.

Kiniksa Pharmaceuticals Investment Alerts

Kiniksa Pharmaceuticals Upcoming and Recent Events

Kiniksa Largest EPS Surprises

View All Earnings Estimates

Kiniksa Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Kiniksa Stock Institutional Investors

Note, although Kiniksa Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Kiniksa Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.7 B.

Kiniksa Profitablity

The company has Profit Margin (PM) of (0.1) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.16) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.16.

Management Efficiency

Kiniksa Pharmaceuticals has return on total asset (ROA) of (0.0515) % which means that it has lost $0.0515 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0985) %, meaning that it created substantial loss on money invested by shareholders. Kiniksa Pharmaceuticals' management efficiency ratios could be used to measure how well Kiniksa Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of March 26, 2025, Return On Tangible Assets is expected to decline to -0.08. In addition to that, Return On Capital Employed is expected to decline to -0.1. At present, Kiniksa Pharmaceuticals' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 261.2 M, whereas Total Assets are forecasted to decline to about 345.8 M.

Technical Drivers

As of the 26th of March, Kiniksa Pharmaceuticals secures the Mean Deviation of 1.84, downside deviation of 2.57, and Risk Adjusted Performance of 0.0822. Kiniksa Pharmaceuticals technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices.

Kiniksa Pharmaceuticals Price Movement Analysis

Kiniksa Pharmaceuticals Insider Trading Activities

Kiniksa Pharmaceuticals Outstanding Bonds

Kiniksa Pharmaceuticals Predictive Daily Indicators

Kiniksa Pharmaceuticals Corporate Filings

Kiniksa Pharmaceuticals Forecast Models

Kiniksa Pharmaceuticals' time-series forecasting models are one of many Kiniksa Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Kiniksa Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Kiniksa Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Kiniksa shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Kiniksa Pharmaceuticals. By using and applying Kiniksa Stock analysis, traders can create a robust methodology for identifying Kiniksa entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Kiniksa analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Kiniksa analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Kiniksa Pharmaceuticals stock analysis indicators help investors evaluate how Kiniksa Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Kiniksa Pharmaceuticals shares will generate the highest return on investment. By understating and applying Kiniksa Pharmaceuticals stock analysis, traders can identify Kiniksa Pharmaceuticals position entry and exit signals to maximize returns.

When running Kiniksa Pharmaceuticals' price analysis, check to measure Kiniksa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiniksa Pharmaceuticals is operating at the current time. Most of Kiniksa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiniksa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiniksa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiniksa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.